RT Journal Article
SR Electronic
T1 SARS-CoV-2 lineage B.1.1.7 is associated with greater disease severity among hospitalised women but not men
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.06.24.21259107
DO 10.1101/2021.06.24.21259107
A1 Stirrup, Oliver T.
A1 Boshier, Florencia A. T.
A1 Venturini, Cristina
A1 Guerra-Assunção, José Afonso
A1 Alcolea-Medina, Adela
A1 Becket, Angela H
A1 Charalampous, Themoula
A1 da Silva Filipe, Ana
A1 Glaysher, Sharon
A1 Khan, Tabassum
A1 Kulasegara-Shylini, Raghavendran
A1 Kele, Beatrix
A1 Monahan, Irene M.
A1 Mollett, Guy
A1 Parker, Matthew
A1 Pelosi, Emanuela
A1 Randell, Paul
A1 Roy, Sunando
A1 Taylor, Joshua F.
A1 Weller, Sophie J.
A1 Wilson-Davies, Eleri
A1 Wade, Phillip
A1 Williams, Rachel
A1 ,
A1 ,
A1 Copas, Andrew J.
A1 Cutino-Moguel, Teresa
A1 Freemantle, Nick
A1 Hayward, Andrew C.
A1 Holmes, Alison
A1 Hughes, Joseph
A1 Mahungu, Tabitha W.
A1 Nebbia, Gaia
A1 Partridge, David G.
A1 Pope, Cassie F.
A1 Price, James R.
A1 Robson, Samuel C.
A1 Saeed, Kordo
A1 de Silva, Thushan I.
A1 Snell, Luke B.
A1 Thomson, Emma C.
A1 Witney, Adam A.
A1 Breuer, Judith
YR 2021
UL http://medrxiv.org/content/early/2021/06/28/2021.06.24.21259107.abstract
AB Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) lineage B.1.1.7 has been associated with an increased rate of transmission and disease severity among subjects testing positive in the community. Its impact on hospitalised patients is less well documented.Methods We collected viral sequences and clinical data of patients admitted with SARS-CoV-2 and hospital-onset COVID-19 infections (HOCIs), sampled 16/11/2020 - 10/01/2021, from eight hospitals participating in the COG-UK-HOCI study. Associations between the variant and the outcomes of all-cause mortality and intensive therapy unit (ITU) admission were evaluated using mixed effects Cox models adjusted by age, sex, comorbidities, care home residence, pregnancy and ethnicity.Results Sequences were obtained from 2341 inpatients (HOCI cases = 786) and analysis of clinical outcomes was carried out in 2147 inpatients with all data available. The hazard ratio (HR) for mortality of B.1.1.7 compared to other lineages was 1.01 (95% CI 0.79-1.28, P=0.94) and for ITU admission was 1.01 (95% CI 0.75-1.37, P=0.96). Analysis of sex-specific effects of B.1.1.7 identified increased risk of mortality (HR 1.30, 95% CI 0.95-1.78) and ITU admission (HR 1.82, 95% CI 1.15-2.90) in females infected with the variant but not males (mortality HR 0.82, 95% CI 0.61-1.10; ITU HR 0.74, 95% CI 0.52-1.04).Conclusions In common with smaller studies of patients hospitalised with SARS-CoV-2 we did not find an overall increase in mortality or ITU admission associated with B.1.1.7 compared to other lineages. However, women with B.1.1.7 may be at an increased risk of admission to intensive care and at modestly increased risk of mortality.Competing Interest StatementNF reports grants from UKRI, during the conduct of the study; personal fees from Aimmune, personal fees from ALK, personal fees from AstraZeneca, personal fees from MSD, personal fees from Sanofi Aventis, personal fees from Novatis, personal fees from Ipsen, personal fees from Gedeon Richter, personal fees from Galderma, personal fees from Vertex, outside the submitted work. The remaining authors do not have any declarations of interest.Funding StatementThis work was supported by the COG-UK consortium, itself receiving funding from UK Research & Innovation, National Institute of Health Research and Wellcome Sanger Institute.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The details of the IRB/oversight body that provided approval or exemption for the research described are given below: This research project has been approved (as a sub-study within the COG-UK HOCI clinical study protocol v5.0) by the National Research Ethics Service Committee (Cambridge South 20/EE/0118). All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe sequence data analysed are included within publicly available datasets (https://www.cogconsortium.uk/data/). However, due to data governance restrictions it is not possible to openly share the associated patient characteristics and clinical outcome data for the analysis described, as these are considered sensitive and full anonymisation is not possible.